KA/EN
Register
Medicines reference
Search
Search
Product

Travozal

Favourites

Tranexamic Acid · Riveka Pharmaceuticals

1 form: coated tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
500 mg, Coated tablet No label dose in the reference yet - Georgia Yes, human
In force until 19 Dec 2030
Human (Ministry of Health, RAMA)
In the register: ტრავოზალი 500 მგ, აბი
№ რ-044516
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Travozal 500 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.4/10
Weak evidence support
vetman assessment

Travozal

500 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label oral tranexamic acid as continued adjunctive treatment for selected canine hyperfibrinolytic bleeding when an oral regimen is clinically appropriate · By mouth
Care settingVeterinary-directed outpatient continuation after the bleeding phenotype, thrombotic risk, renal function and an accurately measurable oral regimen have been assessed
vetman score 5.4/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-044516 · Verified on 16 Oct 2026 Off-label use

A weak but potentially useful oral adjunct for a selected canine hyperfibrinolytic bleeding phenotype. The ingredient has direct canine PK/PD data, but outcome benefit remains uncertain and this whole-only 500 mg form is a poor dose-delivery match outside a narrow weight range.

Regulatory and scientific credibility6.0/10

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Clinical efficacy5.0/10

Direct canine crossover data show oral absorption and reduced fibrinolysis in a laboratory model, but clinical outcome evidence is sparse and mixed. Trials of tranexamic acid in bleeding dogs have not consistently reduced transfusion, bleeding or survival outcomes, so oral use remains a selective adjunct rather than a proven routine therapy.

Safety and tolerability6.0/10

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

Clinical practicality4.0/10

A whole-only 500 mg tablet matches approximately 25-33 kg at the studied 15-20 mg/kg oral exposure, but is poorly measurable for many patients and the regimen may require dosing every 8 hours. Crushing does not validate an unmeasured powder fraction; use a measurable alternative for other doses.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with active intravascular clotting or a current thromboembolic event. An antifibrinolytic can stabilize an unwanted thrombus as well as a haemostatic clot.
  • Tranexamic acid is not a universal haemostatic. Do not delay surgical or procedural source control, resuscitation, diagnostic coagulation assessment or indicated blood-component therapy while giving it.
  • Tranexamic acid is predominantly renally eliminated. Check renal function and hydration and reduce exposure or extend the interval when clearance is impaired; accumulation increases neurologic and thrombotic risk.
  • Use cautiously in patients with a seizure history or neurologic disease. Stop and reassess for myoclonus, twitching, altered mentation or seizures, particularly with high or accumulated exposure.
  • Concurrent prothrombotic products or a strongly hypercoagulable state may add thromboembolic risk. Document the rationale and monitor when combining with coagulation-factor concentrates or other haemostatic drugs.
  • Nausea and vomiting are clinically relevant and can be dose- or administration-rate related; protect the airway in obtunded patients and reassess repeated emesis, aspiration risk or inability to retain oral doses.
  • Stop immediately for suspected hypersensitivity, facial swelling, bronchospasm, collapse or anaphylaxis. A rare canine anaphylactic reaction has been reported and exact human products lack target-animal pharmacovigilance.
  • This exact 500 mg tablet is recorded as whole-only. Do not estimate a smaller dose from an unmeasured fraction of crushed powder; use an accurately measurable formulation when 500 mg is not the intended unit.
Assessment sources
  1. Tranexamic acid market audit2026
  2. Tranexamic acid tablet label2024
  3. Merck antifibrinolytic table2026
  4. Canine tranexamic PK/PD2018
  5. Critical-care tranexamic series2022
  6. Canine hemorrhagic-shock RCT2024
  7. Canine ITP feasibility study2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Tranexamic Acid500 mg
Formulation Type
Coated tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 19 Dec 2030
Human (Ministry of Health, RAMA)
In the register: ტრავოზალი 500 მგ, აბი
№ რ-044516
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Tranexamic Acid
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10–15 mg/kg
off-label
 Dog, Cat Emergency Intravenous slowly
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Initial Triage and Resuscitation of Small Animal Emergency Patients
MSD/Merck Veterinary Manual, 2026

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (26 more) Hide additional products

Same therapeutic group 26

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗